Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRX 1 - Tolerx

X
Drug Profile

TRX 1 - Tolerx

Alternative Names: Anti-CD4 monoclonal antibody - Tolerx; MTRX 1011A; RG 7424; TRX1 - Tolerx

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Oxford
  • Developer Genentech; Tolerx
  • Class Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; CD45 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Cutaneous lupus erythematosus; Rheumatoid arthritis

Most Recent Events

  • 07 Oct 2011 Discontinued - Phase-I for Autoimmune disorders in United Kingdom (Parenteral)
  • 07 Oct 2011 Discontinued - Phase-I for Cutaneous lupus erythematosus in USA (Parenteral)
  • 05 Aug 2008 Genentech initiates enrolment in a phase I trial of MTRX1011A (a modified version of TRX 1) in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top